Caribou Biosciences Inc (CRBU)
1.705
-0.08
(-4.75%)
USD |
NASDAQ |
Jun 17, 11:15
Caribou Biosciences Cash from Financing (TTM): 165.14M for March 31, 2024
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
March 31, 2024 | 165.14M |
December 31, 2023 | 154.30M |
September 30, 2023 | 154.47M |
June 30, 2023 | 19.99M |
March 31, 2023 | 2.785M |
December 31, 2022 | 2.133M |
September 30, 2022 | 2.466M |
Date | Value |
---|---|
June 30, 2022 | 324.50M |
March 31, 2022 | 324.74M |
December 31, 2021 | 433.43M |
September 30, 2021 | 433.05M |
June 30, 2021 | 110.48M |
March 31, 2021 | 111.44M |
December 31, 2020 | 1.735M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
1.735M
Minimum
Dec 2020
433.43M
Maximum
Dec 2021
160.05M
Average
132.87M
Median
Cash from Financing (TTM) Benchmarks
Guardant Health Inc | 477.16M |
Regeneron Pharmaceuticals Inc | -1.420B |
Sangamo Therapeutics Inc | 28.71M |
Vertex Pharmaceuticals Inc | -625.00M |
Bio-Path Holdings Inc | -- |